Karyopharm Therapeutics | KPTI - Zinsaufwendungen Für Schuld





Zinsaufwendungen Für Schuld Veränderung Datum
AbbVie USD 740M 40M 2025-06
Abbott USD 42M 2M 2025-12
Amgen USD 653M 32M 2025-12
AstraZeneca USD 484M 181M 2025-12
BioCryst Pharmaceuticals USD 14.14M 5.53M 2025-12
Bristol-Myers Squibb USD 432M 48M 2025-12
Eli Lilly USD 114.7M 134.3M 2025-09
Enanta Pharmaceuticals USD 1.96M 620K 2024-12
GlaxoSmithKline GBP 188M 21M 2025-12
Incyte USD 582K 10K 2025-12
J&J USD 18M 290M 2025-09
Karyopharm Therapeutics USD 11.38M 2.43M 2024-09
MacroGenics USD 3.34M 2.54M 2025-09
Merck USD 412M 85M 2025-12
Nektar Therapeutics USD 6.02M 420K 2024-09
Novartis USD 304M 23M 2025-12
Novartis USD 281M 8M 2025-09
Pfizer USD 711M 59M 2025-12
Regeneron Pharmaceuticals USD 12.2M 7.1M 2025-12
Roche Holding CHF 304M 7.5M 2025-06
Sangamo BioSciences 97.56M 11.39M 2025-06
Takeda JPY 123.63B 40.49B 2025-12
Tectonic Therapeutic USD 12K 276.99M 2025-12
TG Therapeutics USD 6.53M 187K 2025-12
Ultragenyx Pharmaceutical USD 19M 4.85M 2025-12
Xencor USD 7.35M 311K 2025-12